{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:02:48Z","timestamp":1777950168266,"version":"3.51.4"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["951312"],"award-info":[{"award-number":["951312"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["957283"],"award-info":[{"award-number":["957283"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biopha.2018.10.139","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T05:31:18Z","timestamp":1541395878000},"page":"770-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Molecular targeting for treatment of human T-lymphotropic virus type 1 infection"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-3487","authenticated-orcid":false,"given":"Arash","family":"Soltani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-5250","authenticated-orcid":false,"given":"Seyed Isaac","family":"Hashemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farnaz","family":"Zahedi Avval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvar","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houshang","family":"Rafatpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Abdorahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-5455","authenticated-orcid":false,"given":"Baratali","family":"Mashkani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0005","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2018.10.139_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2016.10.015","article-title":"Reducing the global burden of HTLV-1 infection: an agenda for research and action","volume":"137","author":"Willems","year":"2017","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm1745","article-title":"Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells","volume":"14","author":"Jones","year":"2008","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/v8010005","article-title":"HTLV-1, immune response and autoimmunity","volume":"8","author":"Quaresma","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2018.10.139_bib0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fmicb.2012.00378","article-title":"Pathways of cell-cell transmission of HTLV-1","volume":"3","author":"Pique","year":"2012","journal-title":"Front. Microbiol."},{"issue":"100","key":"10.1016\/j.biopha.2018.10.139_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcancer.2013.11.003","article-title":"HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection","volume":"26","author":"Bangham","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2018.10.139_bib0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0040","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/jmv.24448","article-title":"Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran","volume":"88","author":"Rafatpanah","year":"2016","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0045","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/aid.2011.0248","article-title":"Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis","volume":"28","author":"Azarpazhooh","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.biopha.2018.10.139_bib0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","article-title":"High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey","volume":"52","author":"Rafatpanah","year":"2011","journal-title":"J. Clin. Virol."},{"issue":"39","key":"10.1016\/j.biopha.2018.10.139_bib0055","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/v8020031","article-title":"Molecular studies of HTLV-1 replication: an update","volume":"8","author":"Martin","year":"2016","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0065","first-page":"1531","article-title":"Inflammatory manifestations of HTLV-1 and their therapeutic options, expert rev","volume":"10","author":"Martin","year":"2014","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13760-013-0194-6","article-title":"Clinical features of HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in northeast Iran","volume":"113","author":"Shoeibi","year":"2013","journal-title":"Acta Neurol Belg."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0075","first-page":"21","article-title":"Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia","volume":"4","author":"Bellon","year":"2007","journal-title":"Cancer Genomics Proteom."},{"issue":"8801","key":"10.1016\/j.biopha.2018.10.139_bib0080","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/0140-6736(92)90699-4","article-title":"HTLV-I and uveitis","volume":"339","author":"Mochizuki","year":"1992","journal-title":"Lancet"},{"issue":"8727","key":"10.1016\/j.biopha.2018.10.139_bib0085","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(90)92896-P","article-title":"Infective dermatitis of Jamaican children \u2013 a marker for htlv-I infection","volume":"336","author":"Lagrenade","year":"1990","journal-title":"Lancet"},{"issue":"8569","key":"10.1016\/j.biopha.2018.10.139_bib0090","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0140-6736(87)91362-6","article-title":"T-lymphocyte alveolitis in HTLV-I-associated myelopathy","volume":"2","author":"Sugimoto","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ajo.2006.06.013","article-title":"Giph, immunologic markers, uveitis, and keratoconjunctivitis sicca associated with human T-cell lymphotropic virus type 1","volume":"142","author":"Pinheiro","year":"2006","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood.V99.1.88","article-title":"Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP)","volume":"99","author":"Yamano","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00430-017-0506-1","article-title":"Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia\/lymphoma","volume":"206","author":"Ramezani","year":"2017","journal-title":"Med. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/v10010001","article-title":"HTLV-1, the other pathogenic yet neglected human retrovirus: from transmission to therapeutic treatment","volume":"10","author":"Futsch","year":"2017","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.biopha.2018.10.139_bib0115","doi-asserted-by":"crossref","DOI":"10.3390\/v8060161","article-title":"HTLV-1 infection and adult T-cell leukemia\/lymphoma-a tale of two proteins: tax and HBZ","volume":"8","author":"Giam","year":"2016","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0120","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3390\/v7072793","article-title":"Modes of human T cell leukemia virus type 1 transmission, replication and persistence","volume":"7","author":"Carpentier","year":"2015","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0125","first-page":"153","article-title":"HTLV-I infection: virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals","volume":"5","author":"Rafatpanah","year":"2006","journal-title":"Iran J. Allergy Asthma Immunol."},{"key":"10.1016\/j.biopha.2018.10.139_bib0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fmicb.2013.00271","article-title":"Highlights on distinctive structural and functional properties of HTLV Tax proteins","volume":"4","author":"Romanelli","year":"2013","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152609787847686","article-title":"Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection","volume":"9","author":"Boross","year":"2009","journal-title":"Infect. Disord. Drug. Targets"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0145","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1128\/JVI.77.9.5286-5294.2003","article-title":"Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID\/\u03b3cnull mice: suppression by an inhibitor against NF-\u03baB","volume":"77","author":"Dewan","year":"2003","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0150","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2018.10.139_bib0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/aps.2017.17","article-title":"Human T-cell lymphotropic virus type 1 and its oncogenesis","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0160","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1128\/jvi.66.2.906-913.1992","article-title":"Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation","volume":"66","author":"Pique","year":"1992","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1742-4690-7-99","article-title":"Current concepts regarding the HTLV-1 receptor complex","volume":"7","author":"Ghez","year":"2010","journal-title":"Retrovirology"},{"issue":"8","key":"10.1016\/j.biopha.2018.10.139_bib0170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: cell binding and entry","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2018.10.139_bib0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4614-0980-9_10","article-title":"Molecular mechanisms of HIV entry","volume":"726","author":"Wilen","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"issue":"Pt 2","key":"10.1016\/j.biopha.2018.10.139_bib0180","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1099\/vir.0.82390-0","article-title":"An antibody that blocks human T-cell leukemia virus type 1 six-helix-bundle formation in vitro identified by a novel assay for inhibitors of envelope function","volume":"88","author":"Mirsaliotis","year":"2007","journal-title":"J. Gen. Virol."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0185","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1128\/JVI.02458-07","article-title":"Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry","volume":"82","author":"Mirsaliotis","year":"2008","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0190","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1074\/jbc.M806725200","article-title":"Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry","volume":"284","author":"Lamb","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.139_bib0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/aid.2012.0156","article-title":"Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1","volume":"29","author":"Jinno-Oue","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"20","key":"10.1016\/j.biopha.2018.10.139_bib0200","doi-asserted-by":"crossref","first-page":"12692","DOI":"10.1128\/JVI.79.20.12692-12702.2005","article-title":"Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells","volume":"79","author":"Jones","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2018.10.139_bib0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","article-title":"Viral reverse transcriptases","volume":"234","author":"Menendez-Arias","year":"2017","journal-title":"Virus Res."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0210","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006882","article-title":"HIV-1 reverse transcription","volume":"2","author":"Hu","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5252","key":"10.1016\/j.biopha.2018.10.139_bib0215","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/2261209a0","article-title":"RNA-dependent DNA polymerase in virions of RNA tumour viruses","volume":"226","author":"Baltimore","year":"1970","journal-title":"Nature"},{"issue":"5252","key":"10.1016\/j.biopha.2018.10.139_bib0220","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/2261211a0","article-title":"RNA-dependent DNA polymerase in virions of Rous sarcoma virus","volume":"226","author":"Temin","year":"1970","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.biopha.2018.10.139_bib0225","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00018-010-0346-2","article-title":"Retroviral reverse transcriptases","volume":"67","author":"Herschhorn","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"issue":"51","key":"10.1016\/j.biopha.2018.10.139_bib0230","doi-asserted-by":"crossref","first-page":"20345","DOI":"10.1073\/pnas.1100275108","article-title":"Similarities between long interspersed element-1 (LINE-1) reverse transcriptase and telomerase","volume":"108","author":"Kopera","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047505","article-title":"In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs","volume":"7","author":"Hukezalie","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/jit006","article-title":"Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging","volume":"207","author":"Leeansyah","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109718","article-title":"No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir\/ritonavir with and without nucleoside analogues in the MONET trial","volume":"9","author":"Solomon","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0250","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/PL00000626","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"57","author":"Sluis-Cremer","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2018.10.139_bib0255","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","article-title":"The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS)","volume":"67","author":"De Clercq","year":"2013","journal-title":"Adv. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2018.10.139_bib0260","first-page":"E1","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med. Res. Rev."},{"issue":"49","key":"10.1016\/j.biopha.2018.10.139_bib0265","doi-asserted-by":"crossref","first-page":"40850","DOI":"10.1074\/jbc.R112.389056","article-title":"Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise","volume":"287","author":"Le Grice","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.139_bib0270","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0968-0896(99)00012-7","article-title":"Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase","volume":"7","author":"Titmuss","year":"1999","journal-title":"Bioorg Med. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0275","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1128\/AAC.46.9.3080-3083.2002","article-title":"Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro","volume":"46","author":"Balestrieri","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/322785","article-title":"Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine","volume":"184","author":"Garcia-Lerma","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0285","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00253-007-0919-7","article-title":"HIV-1 reverse transcriptase inhibitors","volume":"75","author":"El Safadi","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.139_bib0290","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/376531","article-title":"Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors","volume":"188","author":"Hill","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.139_bib0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2005.09.001","article-title":"Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia\/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro","volume":"68","author":"Balestrieri","year":"2005","journal-title":"Antivir. Res."},{"issue":"Pt 5","key":"10.1016\/j.biopha.2018.10.139_bib0300","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1099\/0022-1317-78-5-1007","article-title":"AZT inhibits the transmission of human T cell leukaemia\/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro","volume":"78","author":"Macchi","year":"1997","journal-title":"J. Gen. Virol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.10.139_bib0305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0168-1702(01)00285-4","article-title":"Efficacy of 3\u2019-azido 3\u2019deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells","volume":"78","author":"Zhang","year":"2001","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0310","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/bioo.2000.1181","article-title":"Effects of nucleoside analogs on native and site-directed mutants of HTLV type 1 reverse transcriptase","volume":"28","author":"Anantharaman","year":"2000","journal-title":"Bioorg. Chem."},{"issue":"21","key":"10.1016\/j.biopha.2018.10.139_bib0315","doi-asserted-by":"crossref","first-page":"10683","DOI":"10.1128\/JVI.01009-06","article-title":"De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice","volume":"80","author":"Miyazato","year":"2006","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0320","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/JVI.73.12.10289-10295.1999","article-title":"Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy","volume":"73","author":"Taylor","year":"1999","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0325","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.47.5.1774-1775.2003","article-title":"Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V -& I) of the reverse transcriptase","volume":"47","author":"Toro","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.10.139_bib0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-1702(01)00287-8","article-title":"The effect of antiretroviral therapy on HTLV infection","volume":"78","author":"Machuca","year":"2001","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0335","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/AAC.00470-07","article-title":"Effect of phosphonated carbocyclic 2\u2019-oxa-3\u2019-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro","volume":"52","author":"Balestrieri","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2018.10.139_bib0340","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bangham","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0345","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/v2020606","article-title":"Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase","volume":"2","author":"Singh","year":"2010","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0350","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/jvi.71.2.1025-1035.1997","article-title":"Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions","volume":"71","author":"Balakrishnan","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2018.10.139_bib0355","doi-asserted-by":"crossref","first-page":"16212","DOI":"10.1038\/nmicrobiol.2016.212","article-title":"Retroviruses integrate into a shared, non-palindromic DNA motif","volume":"2","author":"Kirk","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.biopha.2018.10.139_bib0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0065-3527(08)60305-X","article-title":"Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity","volume":"52","author":"Wlodawer","year":"1999","journal-title":"Adv. Virus Res."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0365","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1128\/AAC.01361-07","article-title":"Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication","volume":"52","author":"Rabaaoui","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0370","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dkr404","article-title":"Antiviral effect of raltegravir on HTLV-1 carriers","volume":"67","author":"Trevino","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0375","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/AAC.01413-10","article-title":"Integrase inhibitors effective against human T-cell leukemia virus type 1","volume":"55","author":"Seegulam","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.biopha.2018.10.139_bib0380","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1021\/jm500402c","article-title":"Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir","volume":"57","author":"Kuhnert","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0385","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2174\/138161207780618849","article-title":"The protease of human T-cell leukemia virus type-1 is a potential therapeutic target","volume":"13","author":"Tozser","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0390","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood-2005-02-0735","article-title":"Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir","volume":"107","author":"Dewan","year":"2006","journal-title":"Blood"},{"issue":"Pt 7","key":"10.1016\/j.biopha.2018.10.139_bib0395","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1099\/vir.0.82704-0","article-title":"Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases","volume":"88","author":"Sperka","year":"2007","journal-title":"J. Gen. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0400","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2174\/138161212799436421","article-title":"Identification of HIV inhibitors guided by free energy perturbation calculations","volume":"18","author":"Acevedo","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0405","first-page":"2360","article-title":"Constitutive activation of NF-\u03baB in primary adult T-cell leukemia cells","volume":"93","author":"Mori","year":"1999","journal-title":"Blood"},{"issue":"5-6","key":"10.1016\/j.biopha.2018.10.139_bib0410","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/08830180701703364","article-title":"NF-kappaB in pathogenesis and treatment of adult T-cell leukemia\/lymphoma","volume":"26","author":"Horie","year":"2007","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0415","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12185-011-0937-1","article-title":"Molecular mechanisms of HTLV-1 infection and pathogenesis","volume":"94","author":"Yasunaga","year":"2011","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.biopha.2018.10.139_bib0420","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/v3060750","article-title":"Controversies in targeted therapy of adult T cell leukemia\/lymphoma: ON target or OFF target effects?","volume":"3","author":"Nasr","year":"2011","journal-title":"Viruses"},{"issue":"13","key":"10.1016\/j.biopha.2018.10.139_bib0425","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2014-03-560060","article-title":"Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia\/lymphoma","volume":"124","author":"El Hajj","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.biopha.2018.10.139_bib0430","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2014-08-590489","article-title":"ST1926 repression of Tax: ATL targeted treatment?","volume":"124","author":"Cesaire","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.biopha.2018.10.139_bib0435","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.81.16.5214","article-title":"Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription","volume":"81","author":"Kr\u00f6nke","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0440","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/jmv.21028","article-title":"Cyclosporin A inhibits HTLV-I tax expression and shows anti-tumor effects in combination with VP-16","volume":"79","author":"Ozaki","year":"2007","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0445","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2015.06.120","article-title":"Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes","volume":"464","author":"Xiang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0450","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2002-11-3601","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507","volume":"102","author":"Zhang","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2018.10.139_bib0455","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0460","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.biopha.2018.10.139_bib0465","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0470","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2003-07-2440","article-title":"A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients","volume":"103","author":"Moura","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0475","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14712598.2017.1347634","article-title":"Mogamulizumab for the treatment of T-cell lymphoma","volume":"17","author":"Makita","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.139_bib0480","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0485","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0490","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2002-01-0151","article-title":"Bay 11-7082 inhibits transcription factor NF-\u03baB and induces apoptosis of HTLV-I\u2013infected T-cell lines and primary adult T-cell leukemia cells","volume":"100","author":"Mori","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0495","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2004-09-3646","article-title":"Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia","volume":"106","author":"Watanabe","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0500","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.biopha.2018.10.139_bib0505","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0510","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1182\/blood-2010-11-321364","article-title":"Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM\/TSP T lymphocytes","volume":"118","author":"Belrose","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.biopha.2018.10.139_bib0515","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.biopha.2018.10.139_bib0520","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1128\/JVI.78.9.4582-4590.2004","article-title":"Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells","volume":"78","author":"Mori","year":"2004","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.biopha.2018.10.139_bib0525","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","article-title":"Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells","volume":"68","author":"Karthik","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0530","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/leu.2010.315","article-title":"LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia\/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway","volume":"25","author":"Hasegawa","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0535","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cas.12366","article-title":"Targeting DNA damage response in cancer therapy","volume":"105","author":"Hosoya","year":"2014","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.biopha.2018.10.139_bib0540","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/febs.13574","article-title":"Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies","volume":"283","author":"Puigvert","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2018.10.139_bib0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1476-4598-13-205","article-title":"Tax impairs DNA replication forks and increases DNA breaks in specific oncogenic genome regions","volume":"13","author":"Chaib-Mezrag","year":"2014","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0550","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2007-07-104257","article-title":"Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks","volume":"112","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0555","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1073\/pnas.1006423108","article-title":"Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress","volume":"108","author":"Aggarwal","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0560","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-016-0352-4","article-title":"WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells","volume":"9","author":"Moles","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0565","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/nm.4007","article-title":"PARP inhibitors: a treatment option for AML?","volume":"21","author":"Wang","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0570","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-015-0217-2","article-title":"Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells","volume":"8","author":"Bai","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2018.10.139_bib0575","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell."},{"issue":"8","key":"10.1016\/j.biopha.2018.10.139_bib0580","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.leu.2403400","article-title":"Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro","volume":"18","author":"Satou","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2018.10.139_bib0585","first-page":"1083","article-title":"Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia","volume":"62","author":"Tan","year":"2002","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2018.10.139_bib0590","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.biopha.2018.10.139_bib0595","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1158\/0008-5472.CAN-15-0942","article-title":"HTLV-1 bZIP factor RNA and protein impart distinct functions on T-cell proliferation and survival","volume":"75","author":"Mitobe","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2018.10.139_bib0600","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.leukres.2015.10.012","article-title":"YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia\/lymphoma cells","volume":"39","author":"Sasaki","year":"2015","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0605","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2012-05-427773","article-title":"Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia","volume":"121","author":"Chen","year":"2013","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.biopha.2018.10.139_bib0610","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.biopha.2018.10.139_bib0615","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2018.10.139_bib0620","doi-asserted-by":"crossref","first-page":"13389","DOI":"10.1128\/JVI.77.24.13389-13395.2003","article-title":"Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts","volume":"77","author":"Feng","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0625","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-4690-10-52","article-title":"Interferon-\u03b1 (IFN-\u03b1) suppresses HTLV-1 gene expression and cell cycling, while IFN-\u03b1 combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells","volume":"10","author":"Kinpara","year":"2013","journal-title":"Retrovirology"},{"issue":"2\u20133","key":"10.1016\/j.biopha.2018.10.139_bib0630","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000490058","article-title":"Interferon lambda family along with HTLV-1 proviral load, tax, and HBZ implicated in the pathogenesis of myelopathy\/tropical spastic paraparesis","volume":"18","author":"Mozhgani","year":"2018","journal-title":"Neurodegener. Dis."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.10.139_bib0635","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","article-title":"The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran","volume":"250","author":"Rafatpanah","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"24","key":"10.1016\/j.biopha.2018.10.139_bib0640","doi-asserted-by":"crossref","first-page":"13386","DOI":"10.1128\/JVI.02758-13","article-title":"Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation","volume":"87","author":"Cachat","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0645","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1038\/s41598-017-12414-3","article-title":"The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis","volume":"7","author":"Enomoto","year":"2017","journal-title":"Sci. Rep."},{"issue":"26","key":"10.1016\/j.biopha.2018.10.139_bib0650","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.10.139_bib0655","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial","volume":"3","author":"Taylor","year":"2006","journal-title":"Retrovirology"},{"issue":"8","key":"10.1016\/j.biopha.2018.10.139_bib0660","first-page":"2849","article-title":"Arsenic-interferon-\u03b1\u2013triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-\u03baB activation","volume":"96","author":"El-Sabban","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2018.10.139_bib0665","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2002-09-2986","article-title":"Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells","volume":"101","author":"Nasr","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2018.10.139_bib0670","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.biopha.2018.10.139_bib0675","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1084\/jem.20101095","article-title":"Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia","volume":"207","author":"El Hajj","year":"2010","journal-title":"J. Exp. Med."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218354817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218354817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:23:19Z","timestamp":1777875799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218354817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":135,"alternative-id":["S0753332218354817"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.139","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeting for treatment of human T-lymphotropic virus type 1 infection","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.10.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}